Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

Clinical responses to immunotherapy have been associated with augmentation of preexisting immune responses, manifested by heightened inflammation in the tumor microenvironment. However, many tumors have a noninflamed microenvironment, and response rates to immunotherapy in melanoma have been

Saved in:
Bibliographic Details
Published in:Cancer immunology research 2018-02, Vol.6 (2), p.189-200
Main Authors: Ariyan, Charlotte E, Brady, Mary Sue, Siegelbaum, Robert H, Hu, Jian, Bello, Danielle M, Rand, Jamie, Fisher, Charles, Lefkowitz, Robert A, Panageas, Kathleen S, Pulitzer, Melissa, Vignali, Marissa, Emerson, Ryan, Tipton, Christopher, Robins, Harlan, Merghoub, Taha, Yuan, Jianda, Jungbluth, Achim, Blando, Jorge, Sharma, Padmanee, Rudensky, Alexander Y, Wolchok, Jedd D, Allison, James P
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cell Line, Tumor
Combined Modality Therapy
CTLA-4 Antigen - antagonists & inhibitors
CTLA-4 Antigen - immunology
Dactinomycin - administration & dosage
Humans
Immunotherapy - methods
Ipilimumab - administration & dosage
Male
Melanoma - drug therapy
Melanoma - immunology
Melanoma - therapy
Melanoma, Experimental - drug therapy
Melanoma, Experimental - immunology
Melanoma, Experimental - therapy
Melphalan - administration & dosage
Mice
Mice, Inbred C57BL
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical responses to immunotherapy have been associated with augmentation of preexisting immune responses, manifested by heightened inflammation in the tumor microenvironment. However, many tumors have a noninflamed microenvironment, and response rates to immunotherapy in melanoma have been
ISSN:2326-6066
2326-6074
DOI:10.1158/2326-6066.cir-17-0356